Baxter is collaborating with DVC LLC to develop cell-culture based influenza vaccines as part of a U.S. Government contract award to DVC. Baxter will develop seasonal and pandemic vaccines using its vero-cell technology, which has the potential to significantly reduce production time compared to traditional vaccine production methods using embryonated hens’ eggs. The development work will support the licensure of a seasonal vaccine and the completion of clinical trials for a pandemic vacci...